| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Eugenio Cersosimo, Mariam Alatrach, Carolina Solis-Herrera, Baskoy Gozde, John Adams, Andrea Hansis-Diarte, Amalia Gastaldelli, Alberto Chavez, Curtis Triplitt, Ralph A DeFronz. Emergence of a New Gluco-Regulatory Mechanism for Glycemic Control with Dapagliflozin/Exenatide Therapy in Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. 2023-07-22. PMID:37481263. |
our hypothesis was that increased egp in response to sglt2i-induced glycosuria persists for a long period and is not abolished by glp-1 ra stimulation of insulin secretion, glucagon suppression. |
2023-07-22 |
2023-08-14 |
Not clear |
| Xiaoxue Lu, Rongrong Ma, Jinling Zhan, Yaoqi Tia. Structural changes of thermally treated starch during digestion and the impact on postprandial glucose homeostasis. Carbohydrate polymers. vol 318. 2023-07-21. PMID:37479434. |
the insulin response to the intake of thermally treated starch increased (4.73 %-6.83 % higher than the control), whereas the concentration of glp-1, a hormone used to promote insulin secretion, decreased (1.54 %-8.56 % lower than the control). |
2023-07-21 |
2023-08-14 |
mouse |
| Ishani Kapoor, Swara M Sarvepalli, David D'Alessio, Dilraj S Grewal, Majda Hadziahmetovi. GLP-1 Receptor Agonists and Diabetic Retinopathy: A Meta-Analysis of Randomized Clinical Trials. Survey of ophthalmology. 2023-07-16. PMID:37454782. |
we searched clinicaltrials.gov for trials comparing fda-approved glp-1 ras to placebo, insulin, or oral antidiabetic medicine. |
2023-07-16 |
2023-08-14 |
Not clear |
| Ishani Kapoor, Swara M Sarvepalli, David D'Alessio, Dilraj S Grewal, Majda Hadziahmetovi. GLP-1 Receptor Agonists and Diabetic Retinopathy: A Meta-Analysis of Randomized Clinical Trials. Survey of ophthalmology. 2023-07-16. PMID:37454782. |
compared to insulin, glp-1 ra use protected against late-stage dr (rr = 0.38, 95% ci [0.15, 0.98]). |
2023-07-16 |
2023-08-14 |
Not clear |
| Ishani Kapoor, Swara M Sarvepalli, David D'Alessio, Dilraj S Grewal, Majda Hadziahmetovi. GLP-1 Receptor Agonists and Diabetic Retinopathy: A Meta-Analysis of Randomized Clinical Trials. Survey of ophthalmology. 2023-07-16. PMID:37454782. |
analysis of individual glp-1 ras showed albiglutide is responsible for these trends, as it is significantly associated with a higher risk of early-stage dr (rr = 2.18, 95% ci [1.01, 4.67]) compared to placebo and a lower risk of late-stage dr (rr = 0.25, 95% ci [0.09, 0.70]) compared to insulin. |
2023-07-16 |
2023-08-14 |
Not clear |
| Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, Kamel Metwally, Simona Caval. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International journal of molecular sciences. vol 24. issue 13. 2023-07-14. PMID:37445623. |
our aim is to emphasize the active role and main outcomes of glp-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio-metabolic, and renal protection. |
2023-07-14 |
2023-08-14 |
Not clear |
| Ronald J Corbee, Jurriaan J Mes, Govardus A H de Jong, Ronald T M van den Dool, Franka Neumer, Stephan Theis, Guido Bosc. Brush border enzyme hydrolysis and glycaemic effects of isomaltulose compared to other saccharides in dogs. Journal of animal physiology and animal nutrition. 2023-07-14. PMID:37448186. |
three of these saccharides, having close and low-moderate degrees of hydrolysis by brush border enzymes, were also evaluated in vivo for their glycaemic effects by measuring plasma levels of glucose, insulin and glucagon-like peptide 1 (glp-1) 0-180 min after administration of a single dosage after an overnight fast (i.e., isomaltulose, sucrose and maltodextrin in a 3 × 3 latin-square design, in 9 dogs, study 2). |
2023-07-14 |
2023-08-14 |
Not clear |
| Danielle L Jones, Clive J Petry, Keith Burling, Peter Barker, Elizabeth H Turner, Laura C Kusinski, Claire L Mee. Pregnancy glucagon-like peptide 1 predicts insulin but not glucose concentrations. Acta diabetologica. 2023-07-13. PMID:37439859. |
incretin hormones glucagon-like peptide 1 (glp-1) and gastric inhibitory peptide (gip) cause increased insulin secretion in non-pregnant adults, but their role in pregnancy, where there are additional metabolically-active hormones from the placenta, is less clear. |
2023-07-13 |
2023-08-14 |
Not clear |
| Michael A Nauck, Timo D Mülle. Incretin hormones and type 2 diabetes. Diabetologia. 2023-07-10. PMID:37430117. |
in contrast, the insulinotropic potency of glp-1 appears to be much less impaired, such that exogenous glp-1 can stimulate insulin secretion, suppress glucagon secretion and reduce plasma glucose concentrations in the fasting and postprandial states. |
2023-07-10 |
2023-08-14 |
Not clear |
| Tomoko Yamada, Shun-Ichiro Asahara, Maki Kimura-Koyanagi, Yoshikazu Tamori, Naokazu Muramae, Kenta Mori, Mitsumasa Okano, Kazunori Otsui, Kazuhiko Sakaguch. Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes. Diabetology international. vol 14. issue 3. 2023-07-03. PMID:37397904. |
fixed-ratio combination injection therapy (frc) is a fixed-ratio mixture containing basal insulin and glucagon-like peptide-1 receptor agonist (glp-1 ra) in a single injection for the treatment of patients with type 2 diabetes. |
2023-07-03 |
2023-08-14 |
Not clear |
| Tomoko Yamada, Shun-Ichiro Asahara, Maki Kimura-Koyanagi, Yoshikazu Tamori, Naokazu Muramae, Kenta Mori, Mitsumasa Okano, Kazunori Otsui, Kazuhiko Sakaguch. Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes. Diabetology international. vol 14. issue 3. 2023-07-03. PMID:37397904. |
the two types of frc products contain different concentrations and mixing ratios of basal insulin and glp-1 ra. |
2023-07-03 |
2023-08-14 |
Not clear |
| Safaa I Khater, Taghreed N Almanaa, Doaa M Abdel Fattah, Tarek Khamis, Mona M Seif, Naief Dahran, Leena S Alqahtani, Mohamed M M Metwally, Mahmoud Mostafa, Raghad A Albedair, Azza I Helal, Manal Alosaimi, Amany Abdel-Rahman Mohame. Liposome-Encapsulated Berberine Alleviates Liver Injury in Type 2 Diabetes via Promoting AMPK/mTOR-Mediated Autophagy and Reducing ER Stress: Morphometric and Immunohistochemical Scoring. Antioxidants (Basel, Switzerland). vol 12. issue 6. 2023-06-28. PMID:37371950. |
lip-bbr also activated the glp-1 expression, which stimulated insulin biosynthesis. |
2023-06-28 |
2023-08-14 |
rat |
| Sudhir Pandey, Supachoke Mangmool, Warisara Parichatikanon. Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective. Pharmaceuticals (Basel, Switzerland). vol 16. issue 6. 2023-06-28. PMID:37375783. |
upon binding to glp-1 receptor (glp-1r), glp-1 and its analogs exert their effects via adenylyl cyclase-mediated camp elevation and subsequent activation of camp-dependent protein kinase(s) which stimulates the insulin release in conjunction with enhanced ca |
2023-06-28 |
2023-08-14 |
Not clear |
| Nuha A ElSayed, Grazia Aleppo, Vanita R Aroda, Raveendhara R Bannuru, Florence M Brown, Dennis Bruemmer, Billy S Collins, Kenneth Cusi, Marisa E Hilliard, Diana Isaacs, Eric L Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K Lyons, Mary Lou Perry, Priya Prahalad, Richard E Pratley, Jane Jeffrie Seley, Robert C Stanton, Robert A Gabba. Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67. Diabetes care. 2023-06-25. PMID:37356015. |
the following paragraphs have also been added to the section:"insulin is the preferred glucose-lowering agent for the treatment of hyperglycemia in adults with type 2 diabetes with decompensated cirrhosis given the lack of robust evidence about the safety and efficacy of oral agents and noninsulin injectables (i.e., glp-1 ra, dual glp-1/glucose-dependent insulinotropic polypeptide receptor agonist), although a recent 48-week study suggested that a glp-1 ra may be safe in patients with nonalcoholic steatohepatitis (nash) and compensated cirrhosis. |
2023-06-25 |
2023-08-14 |
Not clear |
| Jacob Emil Petersen, Maria Hauge Pedersen, Oksana Dmytriyeva, Emilie Nellemose, Tulika Arora, Maja Storm Engelstoft, Wesley Asher, Jonathan Javitch, Thue W Schwartz, Mette Trauelse. Free Fatty Acid Receptor 1 stimulates cAMP production and gut hormone secretion through Gq-mediated activation of adenylate cyclase 2. Molecular metabolism. 2023-06-22. PMID:37348738. |
free fatty acid receptor 1 (ffar1) is highly expressed in enteroendocrine cells of the small intestine and pancreatic beta islet, where ffar1 agonists function as glp-1 and insulin secretagogues, respectively. |
2023-06-22 |
2023-08-14 |
Not clear |
| Lei Shi, Shuai Meng, Yuan Rua. Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-analysis. Cellular and molecular biology (Noisy-le-Grand, France). vol 69. issue 4. 2023-06-17. PMID:37329543. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) have been approved to treat type 2 diabetes mellitus (t2dm), which have been considered at the same treatment pattern point as basal insulin (bi). |
2023-06-17 |
2023-08-14 |
Not clear |
| Lei Shi, Shuai Meng, Yuan Rua. Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-analysis. Cellular and molecular biology (Noisy-le-Grand, France). vol 69. issue 4. 2023-06-17. PMID:37329543. |
in this context, this work was developed to evaluate the clinical efficacy and safety of glp-1 ras by comparing them with basal insulin. |
2023-06-17 |
2023-08-14 |
Not clear |
| Lei Shi, Shuai Meng, Yuan Rua. Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-analysis. Cellular and molecular biology (Noisy-le-Grand, France). vol 69. issue 4. 2023-06-17. PMID:37329543. |
glp-1 ras were compared with basal insulin in adults with t2dm with inadequate oral anti-hyperglycemic drug control by searching related literature from medline, embase, central, and pubmed databases, which were published from established the datasets to october 2022. |
2023-06-17 |
2023-08-14 |
Not clear |
| Anna Thorsø Larsen, Morten A Karsdal, Kim Henrikse. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss. European journal of pharmacology. 2023-06-17. PMID:37329973. |
these agents have demonstrated beneficial effects on body weight, glucose control, and insulin action mirroring the effects observed with glucagon-like peptide-1 (glp-1) agonist treatment. |
2023-06-17 |
2023-08-14 |
rat |
| Åke Sjöholm, Peter M Nilsso. [Diabetes and cognitive decline - An often overlooked association]. Lakartidningen. vol 120. 2023-06-15. PMID:37317892. |
nasal insulin and glp-1 receptor agonists have also shown promising results, but must be further tested in clinical studies. |
2023-06-15 |
2023-08-14 |
Not clear |